PTS and neoplasm: In contrast to the significant numbers of protein kinase inhibitors approved by FDA or under-pre-clinical and clinical evaluation for cancer treatment, few PTPs inhibitors have demonstrated pre-clinical anti-tumor activity and entered clinical trial for cancer.